“This approval reinforces our commitment to expanding access to complex, high-quality injectables that meet real clinical needs,” said Ankur Shah, Chairman and Managing Director, Invengene Limited. “We believe Sugammadex will play a vital role in improving perioperative outcomes and patient safety in India.”

In addition to Sugammadex, Invengene is also open to partnership opportunities in India for a select portfolio of high-value injectable products including: Decitabine, Parecoxib injection, Tigecycline, Posaconazole, Isavuconazole and Avibactam + Ceftazidime.

Invengene is actively exploring partnerships across India to ensure broad and timely access to these injectables. For partnership inquiries, reach out at bd@invengene.com

About Invengene

Invengene Limited is a research-led pharmaceutical company committed to simplifying complex formulations and expanding access to high-quality medicines worldwide. With operations in over 60 countries, Invengene partners with leading healthcare players through in-licensing, out-licensing, and co-development models.

Backed by strong R&D capabilities and deep regulatory expertise, the company offers agile, end-to-end solutions across multiple dosage forms and therapeutic categories. Its partner-first approach is designed to accelerate development timelines, ensure global compliance, and improve patient outcomes.